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Background: Chronic musculoskeletal pain including osteoarthritis (OA) can significantly 
limit the functional independence of individuals. The spine and hip and knee are 
predominantly affected; management guidelines for each recommend exercise and 
education to support self-management.  
Objectives: This study investigated the effectiveness of a generic exercise and self-
management intervention for people over-50 with hip/knee OA and/or lower back pain 
compared to continued GP management. 
Design: Single blind, cluster randomised controlled trial 
Method: Participants who had previously consulted with hip/knee OA and/or chronic lower 
back pain were recruited from 45 GP practices in SW England. Practices were randomly 
allocated to receive continued GP care (control) or continued GP care and a 6-week group 
exercise and self-management intervention facilitated by a physiotherapist and located in a 
community-based physiotherapy department. The primary outcome measure was the 
Dysfunction Index of the Short Musculoskeletal Functional Assessment (DI-SMFA) measured 
at six month post-rehabilitation. 
Results: 349 participants were recruited and allocated to the intervention (n=170) or control 
(n=179) arms; the attrition rate was 13% at the 6 month primary end-point. One minor 
adverse event in the intervention group that required no medical input was reported. 
Intervention arm participants reported better function at 6 months compared with 









Conclusions: A generic exercise and self-management intervention resulted in statistically 
significant changes in function after six-months compared with GP management alone, but 












Facilitating Activity and Self-management for people with Arthritic knee, hip or lower back 1 
pain (FASA): a cluster randomised controlled trial. 2 
 3 
INTRODUCTION 4 
As the population increases and people live longer, diseases associated with older age pose 5 
a considerable public health issue 
[1]
. Demands on already compromised health services are 6 
likely to grow as individuals seek medical assistance to retain independence and quality of 7 
life. Chronic musculoskeletal pain including osteoarthritis (OA) can significantly limit the 8 
functional independence of individuals, and given that 25% of the population experience 9 
these problems 
[2]
, the socioeconomic impact is immense and the personal impact 10 
significant – musculoskeletal disorders are the single largest cause of years lived with 11 
disability in the UK 
[3]
.  Pressure on the older individual to remain healthy will intensify in 12 
association with the expectations to remain economically active and continue working into 13 
the seventh decade. 14 
 15 
Within primary care approximately one third of general practitioner (GP) consultations are 16 
related to musculoskeletal disorders 
[4]
 the most prevalent of which are OA and chronic low 17 
back pain 
[5]
. These conditions are not life-threatening per se, but the effects of pain-18 
induced immobility and reduced function can contribute to the development and 19 
progression of other serious comorbidities common in the older population (e.g. diabetes 20 
and hypertension) 
[5]
. Furthermore associated anxiety and depression are recognisably 21 
higher in this group 
[6]
. As such, from a public health perspective, reducing the impact of 22 











Although disabling chronic musculoskeletal pain and OA can present in any joint, the hip, 25 
knee and lumbar spine are predominantly affected 
[7]
. Previous research has demonstrated 26 
the effectiveness of exercise and self-management 
[8]
, but most trials tailor interventions for 27 
specific joints (e.g. hip or knee or back). In order to deliver evidence-based treatments 28 
clinicians have either to manage patients on an individual basis or refer to joint-specific 29 
group interventions. Neither option is ideal – the former incurs significant time and financial 30 
cost, whilst the latter often requires patients to wait for appropriate numbers of people to 31 
be referred to allow groups to run. Furthermore, epidemiological data demonstrate that 32 
many older people with degenerative joint problems experience pain and functional 33 
difficulty in other joints, seeking further healthcare input as these present 
[9]
.  34 
 35 
Managing multiple joint presentations simultaneously may reduce the need for repeat visits 36 
to healthcare professionals as advice is frequently similar for differing site presentations. In 37 
addition, widening therapy to cover patients with multiple joint involvement would attract 38 
more patients, enable classes to run more frequently (thus reducing waiting times) and 39 
potentially have a prophylactic effect, as people would be more proactive in exercising the 40 
whole musculoskeletal system.  41 
 42 
NICE guidelines recommend exercise and education to promote self-management of the 43 
condition 
[10]
.  Long-term engagement with exercise, like many lifestyle change 44 
interventions, is generally limited, particularly in the presence of chronic musculoskeletal 45 
pain. Many patients stop exercising once formal interventions cease because of loss of 46 
interest, lack of time and/or facilities, and minimal benefits to pain or function 
[11]
. 47 
Symptoms often return and re-referral for further intervention is common at considerable 48 
cost to health services 
[9]









six-week exercise and self-management intervention (ESCAPE-knee pain) facilitated by a 50 
physiotherapist resulted in clinically and statistically significant improvements in function, 51 
pain and self-efficacy six months post-intervention 
[12]
, which were still apparent 2½ years 52 
later 
[13]
.   53 
The current trial was undertaken to determine whether a modified version of the ESCAPE 54 
programme, FASA – Facilitating Activity and Self-management in Arthritic Pain, based on 55 
social cognitive theory, 
[14]
, was beneficial to people with lower limb OA, chronic low back 56 
pain, or a combination of these presentations. The primary hypothesis was that 57 
participation in the FASA intervention would improve function more effectively than 58 
continued GP management alone.  59 
 60 
METHODS 61 
This trial was conducted and analysed according to a pre-specified protocol 
[15]
 (ISRCTN 62 
registration 66190737). Ethical approval was received from South West 4 Research Ethics 63 
Committee: Reference number 11/SW/0053. Recruitment, intervention and follow-up was 64 
completed in 2016, analysis was completed in 2018. 65 
 66 
Design: A pragmatic, assessor blinded, cluster randomised controlled trial (CRCT) compared 67 
usual GP-led primary care management to a physiotherapist-facilitated exercise and self-68 
management intervention.  69 
 70 
Study sample and recruitment 71 
Broad inclusion criteria were adopted to reflect typical populations in primary care, and 72 
participants were recruited from urban and rural GP practices in South West England. 73 










or radiographic diagnosis of hip and/or knee OA, and/or chronic lower back pain of at least 75 
six months duration. Participants were excluded if they had received physiotherapy in the 76 
preceding 6 months; had lower limb arthroplasty; had unstable medical or psychiatric 77 
disorders; or their level of spoken English would prohibit group participation. 78 
GP practices were recruited via the Clinical Research Network and were asked to perform a 79 
database search and send an invitation letter to all potential participants. Subsequently, 80 
practices were 4-block randomised to either the intervention arm or GP-led management 81 
arm, using random sequence generation by a researcher located remotely who was not 82 
involved in recruitment, assessment, data collection or analysis. Potential participants were 83 
asked to return a reply slip or to telephone the Trial Co-ordinator who responded to 84 
participant queries, screened potential participants, received written consent and arranged 85 
assessment appointments, but was not involved in outcome assessment and remained blind 86 
to individual outcome data. Patient groups were formed from the recruiting practices and 87 
individuals attended at a site local to them. 88 
 89 
The Trial Assessor, a physiotherapist blind to participant allocation, conducted the baseline 90 
assessment at a local community-based out-patient physiotherapy department. The 91 
assessment included administration of all outcome measures, collecting anthropometric 92 
data and a physical assessment to eliminate any serious pathology that would exclude 93 
individuals from participating.  94 
 95 
Sample size calculation: Taking p<0.05 as significant, the study sample size of n=352 was 96 
calculated to have 80% power to detect a 5.7 point absolute difference in the primary 97 
outcome measure, the Dysfunction Index of the Short Musculoskeletal Functional 98 
Assessment (DI-SMFA) 
[16]










intervention and standard care arms. Calculations assumed a mean score of 38 (SD=18) 100 
would be observed in standard care, which is taken from Ponzer et al 
[17]
 in a sample of 30 101 
patients with chronic OA in the hip/knee.  102 
As interventions were randomised at the GP practice level, sample size calculations 103 
accounted for this design, assuming an average of 8 patients would be recruited per GP 104 
practice (based on response of the original ESCAPE trial 
[11]
 with cluster size standard 105 
deviation (SD) of 5.11 (taken from the findings of Hurley at al 
[11]
). Variable cluster sizes were 106 
accommodated using the formula of Eldridge et al 
[17]
 anticipating an attrition rate of 20% at 107 
the individual level by the primary end point, assumed to be independent of response and 108 
cluster size.  We used the same intra-cluster correlation co-efficient (ICC) =0.036 as was 109 
reported by Hurley et al 
[11]
 and assumed an overall response SD = 15.0 (in both arms).  110 
 111 
Intervention arm  112 
The FASA intervention was derived from the ESCAPE-knee programme 
[12], 
with amendments 113 
made to account for the involvement of multiple joints. It consisted of an exercise and self-114 
management intervention lasting 6-weeks (twice weekly), and was delivered by a 115 
physiotherapist (blinded to assessment data) to closed groups of approximately eight 116 
participants. In brief, each session lasted for 60-minutes and included approximately 20-25 117 
minutes of physiotherapist-facilitated group discussion and problem-solving session (with a 118 
supporting handbook) regarding issues of self-management. Topics included activity-rest 119 
cycling, use of ice and heat for pain relief, goal-setting and action plans, exercise 120 
recommendations, healthy eating and managing changes in pain. After each discussion, 121 
participants undertook approximately 30-35 minutes of exercise, based on stations of 122 
strengthening, aerobic and co-ordination activities. Further to the exercises, in collaboration 123 










exercise/activities they aimed to achieve over the following week. This was reviewed after 125 
each week, to determine adherence to the plan, problem-solving if the goal had proved 126 
unachievable, or progressed if it was achieved. Each participant was provided with a 127 
supplementary patient booklet that contained educational materials and self-completed 128 
tasks to monitor their progress. Patients in this arm were also permitted to continue on GP 129 
management and all other treatments as prescribed except physiotherapy. Further details of 130 





All groups were located within typical community-located physiotherapy out-patient 134 
departments, no additional equipment was required, and all were integrated into standard 135 
working hours. Groups were sequentially populated from recruited GP sites, so were 136 
routinely formed from a single GP practice.  137 
 138 
Control arm 139 
Participants allocated to the control arm continued GP-led management, and were 140 
permitted to continue any current pharmacological or non-pharmacological treatment 141 
strategies. New referrals to all other services (e.g. physiotherapy) were also permitted.  142 
 143 
Outcome measures 144 
The primary outcome measure was the Dysfunction Index of the Short Musculoskeletal 145 
Functional Assessment (DI-SMFA) 
[16]
. This validated, self-administered questionnaire was 146 
developed for use in any patients with musculoskeletal dysfunction, recording resultant 147 
actual physical limitation. The 34-item questionnaire asks patients to rate their functional 148 










chosen as it was not joint-specific, and therefore appropriate to use simultaneously in lower 150 
limb and lumbar spine musculoskeletal presentations. The primary analysis related to the 151 
whole patient sample irrespective of site of pain. Efficacy is the overall effect size obtained 152 
from analysis using a mixed model with combined data, not partitioned as per site of pain. 153 
Sub-group analyses of site-specific outcomes were undertaken as secondary analyses. 154 
Secondary outcomes consisted of: Self-efficacy and exercise health beliefs questionnaire 
[20]
; 155 
Hospital Anxiety and Depression scale (HADS) 
[21]
; Short Form McGill Pain questionnaire 
[22]
; 156 
Aggregated Functional Performance Time (AFPT) (a combined measure of walking, stair 157 




All outcomes were collected at baseline and 6 months follow up. All self-completed 160 
outcome measures were also collected post-intervention (and the 6-week equivalent for the 161 
control arm). Baseline assessments were undertaken close to the time of pre-planned class 162 
commencement to prevent significant discrepancy between time period at follow-up 163 
between the control and intervention arms. 164 
 165 
Statistical Analysis 166 
The data analysis plan was based on an a priori protocol 
[15]
 and based on Intention to Treat 167 
with no interim analyses. For the primary analysis, individual patient responses were 168 
modelled using a mixed effects linear regression, allowing for the clustering of outcomes 169 
within GP practices (control arm) and exercise classes (intervention arm) by incorporating a 170 
random effects term. The mixed model was sufficiently robust to handle potential missing 171 
data on the response variable. Differences in mean outcomes from the mixed effects linear 172 
regression were used to estimate the effect on the primary outcome of the intervention. To 173 









as a covariate in the regression. Participants expressed their primary diagnostic site at 175 
baseline (hip/knee/low back pain) which was also included as a covariate to account for 176 
variations in the outcome that may be associated with diagnosis. 177 
The analysis of all other continuous secondary endpoints followed the same structure as the 178 
primary analysis. Whilst the trial was powered to detect a main effect of intervention, a 179 
secondary analysis examined the evidence for a difference in the effect of intervention 180 
between diagnostic groups, by testing whether an interaction term added to the mixed 181 
effects regression model used for the primary analysis was different from zero. 182 
 183 
To better understand its potential benefits, an estimate of the efficacy of the intervention in 184 
those patients who were able and willing to comply using a complier averaged causal effect 185 
(CACE) approach 
[24] 
was undertaken. Here, compliance was measured by attendance at the 186 
12 scheduled exercise classes, and compliers considered as those attending six or more 187 
sessions. This a priori decision was taken based on ‘typical’ class durations in practice 188 
whereby most interventions consist of one session per week over a six-week period. The 189 
CACE approach compared the mean outcome in compliers on the intervention arm with the 190 
mean outcome of a comparable, but unobserved, group of patients on the standard care 191 
arm who would have complied with the intervention had they been randomised to do so.  192 
 193 
RESULTS  194 
Recruitment 195 
In total 56 practices expressed an interest in participating, and 45 consented to take part, 196 
n=23 practices were randomly allocated to the intervention arm, n=22 practices allocated to 197 
the control arm. Database searches identified 4986 potential participants who were sent 198 










participate as the study team did not have ethical permission to access those data. 664 200 
responded and were assessed for eligibility, 232 did not meet the broad inclusion criteria 201 
and a further 45 declined to participate after discussing the trial further. 387 people were 202 
invited for baseline assessment. A further 25 were screened out at this stage as they did not 203 
meet the inclusion criteria or other pathology was suspected and 13 did not attend their 204 
initial assessment or respond to alternative appointments. N=349 of the initial 664 205 
respondents were recruited onto the trial (52.3%). Figure 1 shows the recruitment flow 206 





























Figure 1: CONSORT diagram showing patient recruitment 227 
Assessed for eligibility (n=664) 
Excluded (n=315) 
♦   Not meeting inclusion criteria (n=257) 
♦   Declined to participate (n=45) 
♦   Failed to attend assessment (n=13) 
 
N=143 assessed 
Lost to follow up (n=5) 
• n=2 no reason given 
• n=1 unrelated illness 
• n=1 family illness 
• n=1 time commitments 
N=148 assessed 
Lost to follow up (n=22) 
• n=15 no further contact 
• n=3 unrelated illness 
• n=2 family illness 
• n=2 time commitments 
Allocated to intervention (n=170) 
N=167 assessed 
Lost to follow up (n=12) 
• n=8 no further contact 
• n=4 unrelated illness 
Allocated to control (n=179) 
N=161 assessed 
Lost to follow up (n=6) 
• n=6 unable to contact 
Allocation 
6 month Follow-Up 
6 week Follow-Up 
Randomised (n=349) 
Enrolled Practices N=45 
Intervention= 23 
Control = 22 
 
















One hundred and seventy participants randomly allocated to the intervention arm and 179 233 
to GP-led care (control arm) were broadly similar at baseline (see table 1). At the 6 months 234 
primary end point 27 (16%) participants had withdrawn from the intervention arm and 18 235 
(10%) from the control arm. Total attrition was 13% at the primary end point. No 236 
participants reported withdrawal due to exacerbation of symptoms, although one 237 
participant attended the first six sessions but did not attend remaining sessions due to pain 238 
exacerbation which settled down with rest. She did not however withdraw from the study. 239 
One adverse event was reported in the intervention arm when a participant fell whilst 240 
alighting an exercise bike; no immediate first aid or further intervention was necessary for 241 


























Table 1: Summary of baseline characteristics (means, SD) 259 
Control (n=179)          Intervention (n=170) 260 
Gender, number (Male: Female/% male) 75:104/42%    58:112/34%  261 
Age (years)     66.5 (8.4)   66.3 (8.1) 262 
Height (cm)     167.1 (9.3)   165.8 (9.7) 263 
Weight (kg)     81.0 (15.6)   77.6 (14.0) 264 
DI-SMFA (Irrespective of site of pain) 60.5 (17.2)   60.4 (16.1) 265 
Pain site (DI-SMFA) Hip/Kn only (n=108) 59.1 (15.7)   56.8 (12.2) 266 
   LBP only (n=108) 55.8 (15.7)   58.5 (15.4) 267 
   LBP & hip/kn (n=133) 65.5 (18.4)   64.8 (18.3) 268 
AFPT (secs):  50ft walk  13.2 (4.0)   16.5 (7.9) 269 
   Stair ascent  12.2 (9.5)   13.3 (10.4) 270 
   Stair descent  5.7 (6.0)   5.6 (6.5) 271 
TUAG   9.9 (3.8)   9.9 (3.7) 272 
McGill Pain Questionnaire   2.3 (2.1)   2.2 (2.0) 273 
HADS   Anxiety   5.7 (3.7)   5.6 (3.7) 274 
Depression  4.2 (3.1)   3.9 (2.7) 275 
Self-Efficacy     77.7 (9.4)   78.4 (8.9) 276 
Pain/discomfort    2.4 (0.8)   2.4 (0.8)  277 
Weekly duration on intervention* (mins) 274.4 (17.5)   310.9 (21.3) 278 
DI-SMFA – Dysfunction Index Short Musculoskeletal Functional Assessment; AFPT – Aggregate Functional Performance 279 
Time; HADS – Hospital Anxiety and Depression Scale. *intervention arm patients reported significantly more activity than 280 














Statistical analysis was performed according to the pre-specified data analysis plan and 286 
based on intent-to-treat with no interim or post hoc analyses and no data imputation. 287 
Statistical significance is set at the nominal p-value of 0.05. The means and corresponding 288 
standard deviations were essentially similar for both the treatment and standard arms, 289 
although of note, on average patients in the intervention arm spent more self-reported time 290 
per week (approximately 36 minutes) exercising than control participants.  291 
 292 
Primary and secondary outcomes measured at 6 months primary end point 293 
Results from analysis using the mixed model adjusted for baseline DI-SMFA scores and pain 294 
sites (lower limb, lower back and combined lower back and lower limb) indicate a 295 
statistically significant effect of the intervention on DI-SMFA response measured after 6 296 
months irrespective of pain site (-3.01; 95%CI: -5.25, -0.76, p=0.01) (Table 2). Specifically, 297 
the DI-SMFA score was 3 units lower for a patient on generic exercise and self-management 298 
arm compared with a patient on standard GP care arm, adjusting for both baseline DI-SMFA 299 

















Table 2: Efficacy of exercise on primary and secondary outcomes at primary end point  308 
Analysis  Mean outcome (SD)  Efficacy*  p-value 95% CI 309 
   Control Intervention 310 
A. Primary outcome (DI-SMFA) measured at 6 months 311 
Combined pain sites n=304 312 
Overall efficacy 59.0 (17.9) 56.8 (16.7) -3.01   0.01              -5.25, -0.76 313 
Pain site 314 
Hip/kn only (n=108) 55.7 (14.9) 55.8 (13.0) -2.28   0.15  -5.64, 0.89 315 
LBP only (n=108) 56.3 (20.4) 55.7 (16.7) -4.17   0.16             -10.00, 1.66 316 
LBP & hip/kn (n=133) 62.2 (18.1)  60.2 (14.0) -3.77  0.02              -6.92, -0.61 317 
B. Secondary outcomes measured at 6 months (combined pain sites) 318 
McGill   2.6 (2.1) 2.3 (2.0) -0.23  0.28  -0.65, 0.19 319 
HADS  320 
Anxiety 5.3 (3.8) 5.0 (3.4) -0.21  0.78  -0.91, 0.68 321 
 Depression 3.9 (2.9) 3.7 (2.8) 0.05  0.84  -0.42, 0.52 322 
Self-Efficacy  79.2 (9.8) 80.5 (9.3) 1.69  0.09  -0.27, 3.65 323 
AFPT 324 
50ft walk 13.2 (4.0) 12.5 (2.9) -0.81  0.10  -1.76, 0.15 325 










Stairs descend  5.8 (6.3) 4.9 (4.7) -1.14  0.12  -2.58, 0.30 327 
TUAG  9.6 (3.5) 8.9 (2.7) -0.82  0.04              -1.61, -0.04 328 
*Efficacy: effect size obtained from mixed model analysis 329 
DI-SMFA – Dysfunction Index Short Musculoskeletal Functional Assessment; AFPT – Aggregate Functional Performance 330 
Time; HADS – Hospital Anxiety and Depression Scale 331 
 332 
Considering each pain site, the efficacy of the intervention on the DI-SMFA scores measured 333 
at 6 months was statistically significant among patients presenting with combined LBP and 334 
hip/knee pain (-3.77; 95% CI: -6.92, -0.61; p=0.02) (Table 2). Despite substantial efficacy 335 
from the intervention among patients with both LBP only, and lower limb hip/knee pain 336 
only, these results were not statistically significant (-4.17; 95%CI: -10.0, 1.66; p=0.16 and –337 
2.28; 95%CI: -5.64, 0.89; p=0.15 respectively) (Table 2), but this is to be expected as the 338 
study was not powered for these sub-group analyses and are presented for interest only. 339 
 340 
The results indicate no statistically significant effect of the intervention for all the secondary 341 
outcomes measured at 6 months except for AFPT with respect to Timed Up and Go (TUAG).  342 
Here AFPT scores indicated an improvement of about 1 unit for those patients in the 343 
intervention arm relative to those on control, adjusting for baseline AFPT and baseline type 344 
of pain (-0.82; 95%CI: -1.61, -0.04; p=0.04) (Table 2), but this is unlikely to have clinical 345 
significance. Table 3 shows the means (SD) for the secondary outcomes at each pain site 346 


















Table 3: Secondary outcomes (means, SD) measured at 6 months for each pain site 356 
Outcome         Hip/knee only     LBP only  LBP and hip/knee  357 
         (n=108)     (n=108)      (n=133)                358 
                        Control     Intervtn. Control    Intervtn. Control    Intervtn. 359 
McGill            1.9 (1.5)   1.6 (1.6) 2.6 (2.3)   2.2 (2.0) 3.2 (2.3)   2.9 (2.2) 360 
HADS  361 
Anxiety 4.7 (3.5)   3.9 (3.3) 5.8 (4.0)   5.7 (3.8) 5.5 (3.9)   5.3 (3.1)               362 
Depression 3.5 (2.8)   3.6 (2.6) 3.7 (2.99)   4.1 (2.6) 4.3 (3.1)   3.5 (3.1)  363 
Self-Eff. 78.5 (9.8)  79.9 (9.0) 80.2 (9.3)  80.8 (9.2) 77.7 (9.9)   80.8 (9.8) 364 
AFPT  365 
     50ft walk 12.5 (3.0)   12.7 (3.2) 12.6 (3.6)  11.7 (3.0) 14.2 (4.9)  12.9 (2.5) 366 
     Stairs ascend 12.2 (7.3)  13.4 (12.4) 12.2 (9.8)  12.0 (7.0) 13.7 (11.5)  14.7 (11.7) 367 
     Stairs descend  5.7 (5.6)   4.7 (4.1) 5.3 (6.0)   5.2 (5.2) 6.2 (6.8)   4.9 (4.8) 368 


















Analysis of secondary outcomes at 6 weeks 376 
Analysis of secondary outcomes measured at 6 weeks, adjusted for baseline outcome and 377 
baseline pain sites showed a statistically significant improvement on the McGill pain 378 
questionnaire, Self-efficacy for exercise and the anxiety sub-domain of the HAD (Table 4). 379 
 380 
The results show evidence of statistically significant effects of the intervention on the McGill 381 
Pain Questionnaire measured at 6 weeks (-0.78; 95%CI: -1.30, -0.26; p=0.01): expected 382 
McGill score is about 1 unit lower for patients on exercise and self-management compared 383 
with patients on standard GP care, but this is unlikely to be clinically significant 
(22)
. Similarly, 384 
there is evidence of a statistically significant effect of intervention on self-efficacy measured 385 
at 6 weeks (3.53; 95%CI: 1.45, 5.62; p=0.01): improvement in expected self-efficacy score of 386 
about 3.5 units for patients on exercise and self-management compared with patients on GP 387 
care (Table 4).  388 
 389 
At 6 weeks, there is a statistically significant effect of intervention on HADS with respect to 390 
depression (-0.58; 95%CI: -1.01, -0.14; p=0.01) but not for anxiety (-0.29; 95%CI: -0.92, 0.35; 391 
p=0.38) (Table 4). However, HADS scores (both anxiety and depression) were lower at 6 392 
weeks for patients on treatment compared with patients on GP care, this was not retained 393 
















Table 4: Secondary outcomes analysis at 6 weeks 401 
Outcome  Baseline 6 weeks Efficacy p-value 95% CI 402 
   Mean (SD) Mean (SD) 403 
McGill   3.0 (2.5) 2.3 (2.0) -0.78  <0.01
*
  -1.30, -404 
0.26  405 
HADS  406 
 Anxiety 5.7 (4.1) 5.4 (3.4) -0.29  0.38  -0.92, 0.35 407 
 Depression 4.1 (3.2) 3.5 (2.6) -0.58  <0.01
*
  -1.01, -408 
0.14  409 
Self-Efficacy  77.6 (10.0) 80.9 (8.6) 3.53  <0.01
*
  1.45, 5.62 410 
 411 
Compliance 412 
For the 23 GP surgeries randomised to the experimental intervention, there were 166 413 
records (56 males, 110 female) of compliance with treatment allocation, where a complier 414 
was defined as one who attended at least six (50%) of the scheduled sessions of exercise. 415 
Compliance was considered for most of the patients (83%, 137/166). On average patients 416 
attended 8 sessions of exercise and self-management (Table 5). 417 
 418 
Table 5: Distribution of attendance to intervention for the 12 scheduled sessions 419 
Att. 0    1 2 3 4 5 6 7 8 9 10 11  12                                                                    420 










NB. data not available for 4 participants 422 
 423 
Causal effects of intervention 424 
A complier average causal effect (CACE) analysis provided a measure of the causal effect of 425 
exercise and self-management for patients who received the intervention as intended by 426 
the original group allocation. Under the potential outcomes framework, CACE analysis 427 
compares the mean outcome for compliers in the intervention arm with the mean outcome 428 
of similar (but unobserved) group of patients in the control arm who would have complied 429 
with intervention had they been randomised to do it (counterfactuals).  430 
 431 
We applied the two-stage instrumental variable regression model adjusting for baseline DI-432 
SMFA scores and pain site (as before) and used baseline diagnosis as instruments. Results 433 
for the CACE estimate suggested an improvement in expected DI-SMFA score of about 5.4 434 
units for patients on the intervention (exercise and self-management) compared with 435 
patients on control (standard GP care). 436 
 437 
The CACE estimate is evidently larger than the ITT estimates, demonstrating a greater 438 
benefit of exercise and self-management among participants who complied with the 439 
intervention, i.e. attended at least half (6) of the scheduled sessions (12). 440 
 441 
Primary Outcome / Effectiveness for FASA RCT 442 
In the main effectiveness analyses, the difference in the primary outcome (DI-SMFA score) 443 
was positive, indicating a positive treatment effect associated with intervention 444 












This study determined whether FASA, a generic exercise and self-management intervention 448 
delivered to participants with hip and knee OA and/or chronic lower back had better clinical 449 
outcomes than continued GP-led management. The results demonstrated that participants 450 
on the intervention arm had statistically significantly better function at six months 451 
compared to those on continued GP care arm as measured by the Dysfunction Index of the 452 
Short Musculoskeletal Functional Assessment (DI-SMFA).  453 
To our knowledge this is the first rigorous, pragmatic trial, conducted and analysed 454 
according to a pre-specified protocol 
[15]
 investigating a combined intervention for hip, knee 455 
and/or chronic lower back pain. The trial recruited participants from primary care with a 456 
variety of socio-demographic profiles, and with co-morbidities typical of an older population 457 
affected by chronic and degenerative musculoskeletal disease. The group intervention was 458 
integrated into out-patient physiotherapy departments, was delivered by Chartered 459 
Physiotherapists, and consisted of simple exercises and an interactive educational self-460 
management programme based on behaviour change theory.  461 
 462 
The novelty of this trial was the participant cohort presented with hip, knee or lower back 463 
pain or a combination of these, and were treated with a generic programme. Trials typically 464 
recruit individuals with either one of these presentations, or in some cases with hip and 465 
knee OA pain. This approach is unlikely to reflect typical presentation, when many patients 466 
with chronic, degenerative joint pain either experience concurrent dysfunction in multiple 467 
joints, or over time develop such dysfunction 
[25, 26]
. Furthermore, management guidelines 468 










and self-management, so combining patient presentations seems an appropriate use of 470 
resources.  471 
 472 
The results demonstrated that participating in the FASA intervention had a statistically 473 
significant beneficial effect at the 6-month primary end point on function (DI-SMFA). Whilst 474 
the study was not powered to detect significant changes within sub-groups, it is interesting 475 
to note that those participants who appeared to benefit most from the intervention had 476 
both low back pain and peripheral joint pain and a higher DI-SMFA score. Our previous work 477 
with healthcare professionals to determine the acceptability of the generic FASA 478 
intervention, highlighted professionals had some concerns that it may not be suitable for 479 
people with LBP 
[27]
. This may indicate that professionals’ perceptions are in some cases 480 
over-cautious regarding their management of people with low back pain when generic 481 
approaches to activity may be appropriate. This does not detract from evidence regarding 482 
benefits of stratified management of low back pain, which supports tailored care according 483 
to biopsychosocial presentation 
[28]
, but does highlight the benefit of simple self-484 
management approaches.  485 
 486 
Whilst the results demonstrated participants in the FASA intervention showed statistically 487 
significant improvements in function at 6 months post-intervention, the clinical implications 488 
are less clear due to limited definitive evidence on the minimum clinically important 489 











Some authors have suggested that the MCID for quality of life measures (e.g. SF-36) are 492 
either 3-5 points change in score (based on a 0-100 scale) 
[29]
, whilst others suggest 493 
approximately half of a standard deviation 
[30]
, but there is no conclusive evidence to this 494 
effect for the DI-SMFA. A recent paper reported use of the Dutch version of the SMFA, 495 
which according to the authors has the same item content but a ‘different factor structure’ 496 
[31]
, in a cohort of minor to life-changing trauma patients. The authors reported the 497 
minimum important change (MIC) in the disaggregated sub-scales, suggesting an MIC of 8-498 
25 points. The changes seen within FASA whilst statistically significant may not readily 499 
translate into clinical significance.  500 
The FASA intervention showed limited sustained impact on psychosocial variables. This may 501 
be explained by the low levels of anxiety and depression present in the cohort before the 502 
intervention, thus resulting in a reduced likelihood of meaningful impact on psychosocial 503 
function.  504 
 505 
The strengths of this study were its robust methodology, safety, a priori analysis plan and 506 
pragmatic design, which included participants typically presenting in primary care, and 507 
interventions delivered within NHS physiotherapy departments. The study was limited by 508 
the availability of a widely used musculoskeletal outcome measure that was suitable for 509 
widespread pain presentations. Whilst the SMFA was validated and appropriate for the 510 
study population, the lack of widespread use meant that the MCID was not possible to 511 
determine. However, a supplementary qualitative study did document patient reported 512 
benefit of the intervention (results to be reported separately). This issue is likely resolved 513 
now with the development of the Musculoskeletal Health Questionnaire, which is gaining 514 
momentum, and likely to be used ubiquitously in the near future 
[32]











A further limitation may be the duration of the proposed intervention. NHS services are 517 
under immense pressure to cope with increasing demands on musculoskeletal services with 518 
limited resources, so interventions that require 12 contact sessions may place 519 
unmanageable demand on staff and location resources. However of note is that the original 520 
ESCAPE intervention for lower limb OA has undergone widespread implementation in the 521 
UK 
[33]
, suggesting that such programmes are supported if associated clinical effectiveness is 522 
established. CACE analysis did suggest that patients who attended at least six sessions 523 
achieved a significant improvement in their function, so consideration could be given to 524 
reducing the number of sessions to facilitate implementation within the NHS, but this would 525 
necessitate further robust investigation, and require patients to attend all sessions of a 526 
reduced programme with minimal leeway for missed appointments. Health economic data 527 
collected within this study (to be presented elsewhere), may provide further insight into the 528 
utility of a reduced intervention. 529 
 530 
In summary the FASA intervention resulted in statistically significant functional 531 
improvements, six months post-intervention in a cohort of patients with degenerative lower 532 
limb and/or low back pain. No other statistically significant benefits of the intervention were 533 
noted. We are unable to conclusively suggest that this equates to clinically meaningful 534 
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• FASA results in a statistically significant improvement in function  
• Clinical significance is less clear and requires further investigation 
• This generic exercise and education programme may be a viable clinical option 
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